Rizzo et al., (2010) demonstrated that variant genotype/allele of CYP1B1 4326 C>G polymorphism reduced the sensitivity reaction (7 folds) to taxane treatment as compared to wildtype genotype in breast cancer patients. This evidence concerns the gene CYP1B1 and breast carcinoma.